]. The Canadian Cardiovascular Society / Canadian Heart Failure Society Heart Failure Guidelines recommend the use of an SGLT2 inhibitor in patients with HFrEF, with or without concomitant type 2 diabetes, to improve symptoms and quality of life and to reduce the risk of hospitalization due to heart failure and/or cardiovascular mortality [
]. It is still unknown whether SGLT2 inhibitors can reduce the risk of statin-induced abnormal blood glucose in non-diabetes patients with HFrEF after PCI. Thus, this study aimed to explore the possibility.This is a single-center prospective cohor study. A total of 408 patients who underwent PCI at the Affiliated Hospital of Qingdao University between June 2017 and August 2020 are included.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: